253 related articles for article (PubMed ID: 32978517)
21. Effects of Src kinase inhibition induced by dasatinib in non-small cell lung cancer cell lines treated with cisplatin.
Ceppi P; Papotti M; Monica V; Lo Iacono M; Saviozzi S; Pautasso M; Novello S; Mussino S; Bracco E; Volante M; Scagliotti GV
Mol Cancer Ther; 2009 Nov; 8(11):3066-74. PubMed ID: 19861409
[TBL] [Abstract][Full Text] [Related]
22. Hypoxia-induced antizyme inhibitors 2 regulates cisplatin resistance through epithelia-mesenchymal transition pathway in non-small cell lung cancer.
Shi Q; Chen Q; Zhou Z; Zheng X; Huang X; Fang M; Hu Y; Song L; Yang H; Chen Q
Pulm Pharmacol Ther; 2021 Aug; 69():102048. PubMed ID: 34082109
[TBL] [Abstract][Full Text] [Related]
23. SIRT1 and AMPK mediate hypoxia-induced resistance of non-small cell lung cancers to cisplatin and doxorubicin.
Shin DH; Choi YJ; Park JW
Cancer Res; 2014 Jan; 74(1):298-308. PubMed ID: 24240701
[TBL] [Abstract][Full Text] [Related]
24. Curcumin reverses cis-platin resistance and promotes human lung adenocarcinoma A549/DDP cell apoptosis through HIF-1α and caspase-3 mechanisms.
Ye MX; Zhao YL; Li Y; Miao Q; Li ZK; Ren XL; Song LQ; Yin H; Zhang J
Phytomedicine; 2012 Jun; 19(8-9):779-87. PubMed ID: 22483553
[TBL] [Abstract][Full Text] [Related]
25. Functional cooperation between HIF-1α and c-Jun in mediating primary and acquired resistance to gefitinib in NSCLC cells with activating mutation of EGFR.
Meng S; Wang G; Lu Y; Fan Z
Lung Cancer; 2018 Jul; 121():82-90. PubMed ID: 29858032
[TBL] [Abstract][Full Text] [Related]
26. HIF1α regulated expression of XPA contributes to cisplatin resistance in lung cancer.
Liu Y; Bernauer AM; Yingling CM; Belinsky SA
Carcinogenesis; 2012 Jun; 33(6):1187-92. PubMed ID: 22467238
[TBL] [Abstract][Full Text] [Related]
27. BBI608 inhibits cancer stemness and reverses cisplatin resistance in NSCLC.
MacDonagh L; Gray SG; Breen E; Cuffe S; Finn SP; O'Byrne KJ; Barr MP
Cancer Lett; 2018 Aug; 428():117-126. PubMed ID: 29653268
[TBL] [Abstract][Full Text] [Related]
28. Eukaryotic initiation factor 5A2 mediates hypoxia-induced autophagy and cisplatin resistance.
Xu G; Chen H; Wu S; Chen J; Zhang S; Shao G; Sun L; Mu Y; Liu K; Pan Q; Li N; An X; Lin S; Chen W
Cell Death Dis; 2022 Aug; 13(8):683. PubMed ID: 35931669
[TBL] [Abstract][Full Text] [Related]
29. Ursolic acid inhibits proliferation and reverses drug resistance of ovarian cancer stem cells by downregulating ABCG2 through suppressing the expression of hypoxia-inducible factor-1α in vitro.
Wang WJ; Sui H; Qi C; Li Q; Zhang J; Wu SF; Mei MZ; Lu YY; Wan YT; Chang H; Guo PT
Oncol Rep; 2016 Jul; 36(1):428-40. PubMed ID: 27221674
[TBL] [Abstract][Full Text] [Related]
30. Hypoxia-induced increases in A549/CDDP cell drug resistance are reversed by RNA interference of HIF-1α expression.
Min L; Chen Q; He S; Liu S; Ma Y
Mol Med Rep; 2012 Jan; 5(1):228-32. PubMed ID: 21964646
[TBL] [Abstract][Full Text] [Related]
31. The involvement of XPC protein in the cisplatin DNA damaging treatment-mediated cellular response.
Wang G; Dombkowski A; Chuang L; Xu XX
Cell Res; 2004 Aug; 14(4):303-14. PubMed ID: 15353127
[TBL] [Abstract][Full Text] [Related]
32. Oroxylin A increases the sensitivity of temozolomide on glioma cells by hypoxia-inducible factor 1α/hedgehog pathway under hypoxia.
Wei M; Ma R; Huang S; Liao Y; Ding Y; Li Z; Guo Q; Tan R; Zhang L; Zhao L
J Cell Physiol; 2019 Aug; 234(10):17392-17404. PubMed ID: 30790292
[TBL] [Abstract][Full Text] [Related]
33. Self-targeted knockdown of CD44 improves cisplatin sensitivity of chemoresistant non-small cell lung cancer cells.
Quan YH; Lim JY; Choi BH; Choi Y; Choi YH; Park JH; Kim HK
Cancer Chemother Pharmacol; 2019 Mar; 83(3):399-410. PubMed ID: 30515553
[TBL] [Abstract][Full Text] [Related]
34. Knockdown of REV3 synergizes with ATR inhibition to promote apoptosis induced by cisplatin in lung cancer cells.
Jiang HG; Chen P; Su JY; Wu M; Qian H; Wang Y; Li J
J Cell Physiol; 2017 Dec; 232(12):3433-3443. PubMed ID: 28075014
[TBL] [Abstract][Full Text] [Related]
35. Activation of PI3 kinase/Akt/HIF-1α pathway contributes to hypoxia-induced epithelial-mesenchymal transition and chemoresistance in hepatocellular carcinoma.
Jiao M; Nan KJ
Int J Oncol; 2012 Feb; 40(2):461-8. PubMed ID: 21922131
[TBL] [Abstract][Full Text] [Related]
36. ABCC5, ERCC2, XPA and XRCC1 transcript abundance levels correlate with cisplatin chemoresistance in non-small cell lung cancer cell lines.
Weaver DA; Crawford EL; Warner KA; Elkhairi F; Khuder SA; Willey JC
Mol Cancer; 2005 May; 4(1):18. PubMed ID: 15882455
[TBL] [Abstract][Full Text] [Related]
37. Combination treatment of FTY720 and cisplatin exhibits enhanced antitumour effects on cisplatin-resistant non-small lung cancer cells.
Li Y; Hu T; Chen T; Yang T; Ren H; Chen M
Oncol Rep; 2018 Feb; 39(2):565-572. PubMed ID: 29207165
[TBL] [Abstract][Full Text] [Related]
38. Curcumin downregulates p38 MAPK-dependent X-ray repair cross-complement group 1 (XRCC1) expression to enhance cisplatin-induced cytotoxicity in human lung cancer cells.
Tung CL; Jian YJ; Chen JC; Wang TJ; Chen WC; Zheng HY; Chang PY; Liao KS; Lin YW
Naunyn Schmiedebergs Arch Pharmacol; 2016 Jun; 389(6):657-66. PubMed ID: 27026405
[TBL] [Abstract][Full Text] [Related]
39. CHD1L contributes to cisplatin resistance by upregulating the ABCB1-NF-κB axis in human non-small-cell lung cancer.
Li Y; He LR; Gao Y; Zhou NN; Liu Y; Zhou XK; Liu JF; Guan XY; Ma NF; Xie D
Cell Death Dis; 2019 Feb; 10(2):99. PubMed ID: 30718500
[TBL] [Abstract][Full Text] [Related]
40. Wilms' tumor 1 enhances Cisplatin-resistance of advanced NSCLC.
Wu C; Wang Y; Xia Y; He S; Wang Z; Chen Y; Wu C; Shu Y; Jiang J
FEBS Lett; 2014 Dec; 588(24):4566-72. PubMed ID: 25447528
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
